Holen Sie sich die Stockscreener-App
6.83
0.72%
-0.09
Schlusskurs vom Vortag:
$6.92
Offen:
$6.9
24-Stunden-Volumen:
236.19K
Relative Volume:
0.19
Marktkapitalisierung:
$511.57M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.03M
KGV:
-12.20
EPS:
-0.56
Netto-Cashflow:
$-23.97M
1W Leistung:
-6.15%
1M Leistung:
-20.76%
6M Leistung:
+64.35%
1J Leistung:
+21.59%
1-Tages-Spanne:
$6.85
$7.00
1-Wochen-Bereich:
$6.43
$7.355
52-Wochen-Spanne:
$2.54
$9.60
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Firmenname
Corvus Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 900-4520
Adresse
863 MITTEN ROAD, BURLINGAME, CA
Vergleichen Sie CRVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
6.85 | 516.80M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.17 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.36 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.32 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-01-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-18 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-05-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-05-29 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-04-18 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
Can Corvus Pharmaceuticals Inc. stock reach $100 price targetJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - ulpravda.ru
Is Corvus Pharmaceuticals Inc. stock ready for breakoutIndex Update & Risk Controlled Swing Alerts - ulpravda.ru
Will Corvus Pharmaceuticals Inc. stock outperform international peers2025 AllTime Highs & AI Powered Market Entry Strategies - ulpravda.ru
Will Corvus Pharmaceuticals Inc. stock gain from lower inflationQuarterly Portfolio Summary & Safe Entry Trade Reports - ulpravda.ru
Is Corvus Pharmaceuticals Inc. stock a good choice for value investorsJuly 2025 Update & Accurate Intraday Trade Tips - ulpravda.ru
How supply chain issues affect Corvus Pharmaceuticals Inc. stockMarket Movement Recap & Capital Efficiency Focused Strategies - ulpravda.ru
Should I hold or sell Corvus Pharmaceuticals Inc. stock in 20252025 Key Lessons & Reliable Entry Point Trade Alerts - ulpravda.ru
Hedge Fund Moves: Is Corvus Pharmaceuticals Inc stock ready for breakout2025 Winners & Losers & Technical Pattern Alert System - moha.gov.vn
Can Corvus Pharmaceuticals Inc. stock beat analyst upgradesMarket Volume Summary & Technical Buy Zone Confirmation - ulpravda.ru
Corvus Pharmaceuticals to announce atopic dermatitis trial results in January By Investing.com - Investing.com Nigeria
Both Retail Investors Who Control a Good Portion of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Along With Institutions Must Be Dismayed After Last Week's 9.3% Decrease - 富途牛牛
Both retail investors who control a good portion of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) along with institutions must be dismayed after last week's 9.3% decrease - simplywall.st
Corvus Pharmaceuticals to announce atopic dermatitis trial results in January - Investing.com
Corvus Pharmaceuticals Confirms Plans to Announce Results - GlobeNewswire
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5%Should You Sell? - MarketBeat
Is Corvus Pharmaceuticals Inc a good long term investmentInsider Trading Activity & Free Real-Time Trading Signals - earlytimes.in
How strong is Corvus Pharmaceuticals Inc. stock balance sheetRetail Trading Trends & Free Trading Signals to Sharpen Your Edge - bollywoodhelpline.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 3.5% – Still a Buy? - Defense World
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 3.5%Here's Why - MarketBeat
Corvus Pharmaceuticals, Inc.(NasdaqGM:CRVS) added to S&P Biotechnology Select Industry Index - MarketScreener
IPO Launch: Will Corvus Pharmaceuticals Inc. stock split attract more investors2025 Earnings Surprises & Reliable Intraday Trade Plans - moha.gov.vn
Will Corvus Pharmaceuticals Inc. stock split attract more investorsJuly 2025 Selloffs & Real-Time Stock Movement Alerts - Улправда
Aug Macro: Why Corvus Pharmaceuticals Inc. stock appeals to dividend seekersJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - Улправда
Hedge Fund Moves: How strong is Corvus Pharmaceuticals Inc. stock balance sheet2025 Sector Review & Momentum Based Trading Signals - ulpravda.ru
Street Watch: Will Corvus Pharmaceuticals Inc. stock split attract more investors2025 Sector Review & Daily Stock Trend Watchlist - Улправда
- ulpravda.ru
Corvus Pharmaceuticals Earnings Notes - Trefis
Corvus Pharmaceuticals stock awaits key January 2026 trial data By Investing.com - Investing.com Canada
What is Corvus Pharmaceuticals Inc (CRVS) Stock Return on Shareholders’ Capital? - setenews.com
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 7.1% HigherWhat's Next? - MarketBeat
Corvus Pharmaceuticals Reports Promising Phase 1 Data for Soquelitinib in Relapsed/Refractory T Cell Lymphoma at ASH Annual Meeting - Quiver Quantitative
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial - The Manila Times
Corvus Pharma (CRVS) Stock Analysis Report | Financials & Insights - Benzinga
Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 12-Month HighHere's What Happened - MarketBeat
You might want to take a look at Corvus Pharmaceuticals Inc (CRVS) now - setenews.com
Will Corvus Pharmaceuticals Inc. stock split again soonMarket Performance Report & Growth Focused Investment Plans - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8%Here's What Happened - MarketBeat
Here's Why We're Not Too Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation - Yahoo Finance
Is Corvus Pharmaceuticals Inc. stock a buy before product launchesDividend Hike & Intraday High Probability Alerts - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Perhaps timely catching Corvus Pharmaceuticals Inc (CRVS) would be a good idea - Setenews
Foresite Capital Management VI LLC Boosts Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals: Trial Momentum Keeps Stock In Focus - RTTNews
What risks investors should watch in Corvus Pharmaceuticals Inc. stockWeekly Trend Summary & Weekly Watchlist for Consistent Profits - newser.com
Will Corvus Pharmaceuticals Inc. stock reach Wall Street targetsPortfolio Growth Summary & Technical Buy Zone Confirmation - newser.com
Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):